



Pharmaceutical Sciences World Congress

**3rd World Congress
of the Board of Pharmaceutical Sciences
of FIP (PSWC 2007)**

Optimising Drug Therapy: An Imperative for World Health

**Congress venue and dates:
RAI Congress Centre,
Amsterdam, The Netherlands
from 22-25 April 2007**

www.fip.org/PSWC

Organising Committee

Chair:

Daan Crommelin (The Netherlands)

Secretary:

Vinod Shah (USA)

Program Co-Chairs:

Geoffrey Tucker (UK)
Tomohiko Ohwada (Japan)

Finance/Fund-Raising Co-Chairs:

Theo Dingermann (Germany)
Dick Gourley (USA)
Mitsuru Hashida (Japan)

Publicity/Hospitality Co-Chairs:

Dominique Duchêne (France)
Jun Haginaka (Japan)
Mario Rocci (USA)

Scientific Advisory Committee:

Leslie Benet (USA)
Douwe Breimer (The Netherlands)
Kamal Midha (Canada)
Tsuneji Nagai (Japan)
Malcolm Rowland (UK)
Yuichi Sugiyama (Japan)

Organisation and Exhibition:

International Pharmaceutical Federation (FIP):
Ton Hoek and Gretie R.v.d. Baumen
(The Netherlands), in close co-operation with
EUFEPS: Hans Linden (Sweden)

Local Committee:

Meindert Danhof, Bert Leufkens, Ben Westerink
(The Netherlands)

Co-Sponsoring Organisations

European Federation for Pharmaceutical Sciences
(EUFEPS)
American Association of Pharmaceutical Scientists
(AAPS)
Association de Pharmacie Galénique Industrielle
(APGI)
Academy of Pharmaceutical Sciences of Great Britain
(APSGB)
Academy of Pharmaceutical Science and Technology,
Japan (APSTJ)
Australasian Pharmaceutical Science Association
(APSA)
Controlled Release Society (CRS)
Pharmaceutical Society of Japan (PSJ)
Supporting Organisations
International Society for the Study of Xenobiotics
International Society for Pharmacoeconomics
European Society of Clinical Pharmacy

For further information on all other matters:

FIP Congress & Conferences
Andries Bickerweg 5 Tel.: +31-70-3021982
P.O. Box 84200 Fax: +31-70-3021998
2508 AE The Hague (The Netherlands)
E-mail: congress@fip.org

Outline Congress Schedule

Sunday, 22 April, 2007

All day

Registration
Opening Ceremony
Distinguished Lectures
Scientific Awards

Evening

Welcome Reception

Monday, 23 until Wednesday, 25 April, 2007

All Day
Symposia
Exhibition and Posters
Round Table Sessions
Debates
Plenary Lectures

Provisional Programme

Opening Ceremony:

Thought leaders in the pharmaceutical sciences

Keynote Lectures:

GLOBAL MEDICAL NEEDS

1. What are the main challenges for world health?
2. Are we meeting the challenges of resistance to anti-infective drugs and of newly emerging infectious agents?
3. What are the frontiers in the development of cancer treatment?
4. Will an understanding of the molecular genetic basis of neurodegenerative disease lead to effective treatments?
5. Will novel approaches to the treatment of cardiovascular disease prove highly effective?
6. How to transform art into science in dosage form design?

Symposia:

A. FUTURE THERAPIES

1. Personalised Medicine

1. The era of personalised health care: Impact on drug discovery and development?
2. Pharmacogenetics at the bedside?
3. What is the value of medical informatics/data mining?
4. Drug-drug interactions: Avoid or understand?
5. How to manage drug therapy at the extremes of age?
6. Is the patient taking the tablets?

2. Novel Therapies

1. Is gene/protein delivery delivering?
2. What will the impact of cell-based therapy be?

3. Novel Formulations and Delivery Systems

1. How can nanotechnology and materials science solve drug delivery problems?
2. What is the future for smart drug delivery systems?
3. Drug targeting: how successful are we?

B. PHARMACEUTICAL SCIENCES: ENABLING RESEARCH AND TECHNOLOGY

1. Target Design/Medicinal Chemistry

1. Systems biology: A driver of drug discovery and development?
2. How will developments in new synthetic reactions and process chemistry sustain industrial development?
3. What is the state-of-the-science in receptor active site modelling?
4. Have genomics technologies improved the chance for successful drug development?
5. Molecular targeting in cancer: Chemotherapy?
6. Are non-selective drugs and multi-targeting the way forward in CNS drug design?

2. Pharmacokinetics/Pharmacodynamics

1. Can ADME and PK be predicted from In Silico/In Vitro data?
2. Simulation and modelling save time and money in clinical development?
3. What's new in methods of measuring drug response?
4. How does disease influence PK-PD?
5. How important is genetic and physiological variability in drug transporters?
6. Control of intracellular trafficking: Pharmacokinetic advantages?

3. Pharmaceutical Technology

1. How to engineer desired particle properties for drug delivery?
2. In silico product development from molecule to man - dream or reality?
3. Are pharmaceutical manufacturing technologies in stagnation?
4. Developing biotech products: What are the challenges and solutions?

4. Pharmaceutical Analysis/Quality Assurance/ Regulatory Affairs

1. What are the most effective analytical approaches for biomarker discovery and metabonomics?
2. Miniaturisation in analytical approaches: Small is beautiful?
3. What benefits does Process Analytical Technology (PAT) bring to process design and assurance of product quality?
4. Counterfeiting of medicines: Detection and prevention?

5. Clinical Pharmacology/Epidemiology

1. What have we learnt from recent safety failures for new drug development?
2. How effective is the globalisation/harmonisation of pharmacovigilance?
3. Nutraceuticals: Are new models for evaluating risk/benefit required?

4. Are we using the right outcome measures to ascertain patient benefit of drug therapy?
5. Off-label use of medicines: Abuse or a vehicle for innovation?

Debates / Round Table Sessions

1. Science or business as the driver of new drug development?
2. Life-style drugs: a new burden to the health system?
3. Can we afford new drug delivery technologies?
4. Vaccines: what will their contribution be to health care?
5. Does regulation help to 'innovate or stagnate' drug development?
6. Is there a consensus on guidelines for the evaluation of biogenics?
7. What are the added values of randomised clinical trials and observational studies in assessing drug effectiveness and safety?
8. When is a human bioequivalence study not needed?
9. How can the bioavailability of a poorly absorbed compound be enhanced?
10. How far can animal toxicology be replaced by in vitro testing?
11. Can microdosing accelerate drug development?
12. New excipients: Do we need them?

Poster Session and Exhibition

Participants are invited to submit contributions for poster presentations. A limited number of contributions will be selected as podium presentations in the symposia. Each day approximately 500 Posters will be presented in the RAI Conference Centre.

Pre-satellite Sessions

Pre-satellite symposium for and by Ph.D. students and postdoctoral fellows

Dates: **20 and 21 April, 2007**

Chair Organising Committee:
Stefaan De Smedt (Belgium)

Information Pre-satellite Symposium:
stefaan.desmedt@ugent.be

Hotels

Through RAI Hotel & Travel Service of Amsterdam, rooms in 5, 4, and 3 star Hotel categories have been blocked. A number of these hotels offer triple room occupation. Further information can be obtained from RAI Hotel & Travel Service.
E-mail: m.vd.weegen@rai.nl